BRIEF-Treace Medical Q4 EPS USD -0.15
TMCI sits 18% above its 52-week low of $1.81.
Summary
Treace Medical reported its Q4 results, with revenue reaching $62.519 million, surpassing IBES estimates of $61.4 million. The company also posted a gross profit of $50.401 million and an EPS of -$0.15. The revenue beat indicates stronger-than-expected top-line performance, which is a positive for the company. However, the negative EPS highlights continued unprofitability, which investors will monitor closely. Traders will be assessing whether the company's revenue growth trajectory can lead to profitability in the near future.
At the time of this announcement, TMCI was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.8M. The 52-week trading range was $1.81 to $10.03. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.